NextGen 2024: Genetics in SJIA Session Part 1
NextGen 2024: Genetics in SJIA Session Part 1
- Genetics play a significant role in systemic juvenile idiopathic arthritis (sJIA) and macrophage activation syndrome (MAS).
- Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome
- Mutations in genes like PRF1 can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.
- Certain genes like UNC13D, STXBP2, and PRF1 are implicated in HLH genetics of MAS patients
- Genetic knowledge is valuable in sJIA/MAS for understanding disease mechanisms, assessing recurrence risk, and genetic counseling.
NextGen 2024: Genetics in SJIA Session Part 1
@SJIA_Foundation3 months ago
'Clinical Utility of Genetics in Systemic JIA'
Randy Q. Cron, MD, PhD University of Alabama at Birmingham
NextGen Conference 2024
Washington, D.C.


THE UNIVERSITY OF
- · IRF5 , IL1RN , HLA-DRB1*15 - Ombrello
- · HLH gene associations (e.g. PRF1 , UNC13D )
- · Potential explanation for diminished NK cell cytolyic function
- · Risk of recurrence
- · Genetic counseling
- · One nucleotide change, even missense, does not necessarily â¦
- · Rarity of mutation
- · Prediction of disruption (e.g. PolyPhen-2)
- · Prior publication of MAS/HLH association
- · Test individual mutations in lab (e.g. in vitro )
Disclosures
Randy Q. Cron, M.D., Ph.D.
SOBI - investigator initiated clinical trial of anakinra to treat MAS
SOBI - advisory board for MAS therapy
SOBI - paid speaker/moderator for MEDSCAPE/WebMD
Novartis - consultant on switching therapy
Pfizer - clinical trial MAS adjudication committee chair
Sironax - consultant on RIP1 inhibitor
AbbVie - clinical trial MAS adjudication committee member
Lilly - paid speaker
CareerPhysician - advisory council
American Board of Pediatrics - Subboard of Pediatric Rheumatology
Springer - royalties on Cytokine Storm Syndrome textbook



juvenile rheumatoid arthritis and macrophage activation syndrome

Alexei A Grom, Joyce Villanueva, Susan Lee, Ellen A Goldmuntz, Murray H Passo, Alexandra Filipovich.
Grom
J Pediatr. 2003 Mar;142(3):292-6.

Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome.
Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA.
Arthritis Res Ther. 2005;7(1):R30-7.
juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms.

Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo
Zhang
MH, Binstadt BA, Filipovich A, Grom AA. Arthritis Rheum. 2008 Sep;58(9):2892-6.
9/16 sJIA/MAS patients (57%) vs. 6/73 sJIA without MAS (8.2%) vs.
27/229 healthy controls (12%)

1047 aa Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Hazen MM, Woodward AL, Hofmann I, Degar BA, Grom A, Filipovich AH, Binstadt BA. Arthritis Rheum . 2008 Feb;58(2):567-70.
Novel UNC13D intronic variant disrupting a NFκB enhancer in a patient with recurrent macrophage activation syndrome and systemic juvenile idiopathic arthritis Grant S Schulert , Mingce Zhang, Ammar Husami, Ndate Fall, Hermine Brunner, Kejian Zhang, Randy Q Cron, Alexei A Grom. Arthritis Rheumatol . 2018 May 2;70(6):963-970

RHEUMATOLOGY
Original article
Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis
Sebastiaan J. Vastert',2 Richard van Vooght , Wilco de Jager',2 Angelo Ravellis , 4 Silvia Magni-Manzonis , Antonella Insalacos Elisabetta Cortis Wouter W_ van Solinge3 Berent J. Prakken',2 Nico M Wulffraat',2 Fabrizio de Benedetti4 and Wietse Kuis',2

PRF1 A91V mutation sJIA/MAS - 20% vs. sJIA no MAS - 10%


Almost 20% of the SoJIA patients harbour heterozygous mutations In PRF1
HLH Genetics of MAS Patients at Children's of Alabama


Whole Exome Sequencing Reveals Overlap Between Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Familial Hemophagocytic
Lymphohistiocytosis
Kenneth M. Kaufman1,4 Bolan Ammar Husami2 Fan and Alexei A. Grom1

Heterozygous FHL gene mutations:
5/14 sJIA/MAS - 36% vs.
4/29 sJIA no MAS - 14%
Role of DOCK8 in Cytokine Storm Syndromes.
Zhang M, Cron RR, Chu N, Nguyen J, Gordon SM, Eloseily EM, Atkinson TP, Weiser P, Walter MR, Kreiger PA, Canna SW, Behrens EM, Cron RQ.
J Allergy Clin Immunol . 2024. Online ahead of print.


A
Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis Arthritis & Rheumatology
Mariana Correia Marques, Mallika Datta, Elizabeth Schmitz, 1 3 4 ID Gustavo Gutierrez Cruz, Andrew Patt, Elizabeth Bennett, Alexei Grom, Dirk Foell, Marco Gattorno; 6 Sampath Prahalad; ' iD Elizabeth Mellins 8 Jordi Anton,? Claudio A. Len,10 Zuoming Deng Michael J. Ombrello; 1 INCHARGE Consortium Yeung

MAS Genetics in Systemic JIA

The genetics of macrophage activation syndrome The genetics of macrophage activation syndrome
Grant 5 Schulrt' Grant 5 Schulert'
Randy Q Cron'
The Multifaceted Immunology of Cytokine Storm Syndrome
and Randy Q Cron
The Journal of Immunology 2023, 210: 1015-1024

Value of genetic knowledge in sJIA/MAS













Related Jaunts

NextGen 2024: Unmet Needs & Clinical Trial Challenges Session Part 1
@SJIA_Foundation

NextGen 2024: Weaning meds when disease is controlled Session Part 2
@SJIA_Foundation

Current treatments in macrophage activation syndrome - METAPHOR projec
@rashmi

NextGen 2024: Monitoring &Treating Lung Disease in SJIA Session Part 2
@SJIA_Foundation

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 1
@SJIA_Foundation

NextGen 2024: Monitoring &Treating Lung Disease in SJIA Session Part 1
@SJIA_Foundation
More from author

NextGen 2024: Weaning meds when disease is controlled Session Part 2
@SJIA_Foundation

NextGen 2024: Weaning meds when disease is controlled Session Part 1
@SJIA_Foundation

NextGen 2024: Monitoring &Treating Lung Disease in SJIA Session Part 2
@SJIA_Foundation

NextGen 2024: Monitoring &Treating Lung Disease in SJIA Session Part 1
@SJIA_Foundation

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 5
@SJIA_Foundation

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 4
@SJIA_Foundation

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 3
@SJIA_Foundation

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 2
@SJIA_Foundation
